Zentalis Pharmaceuticals, Inc.
ZNTL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $1 | $1 | $4 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $1 | $1 | $4 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -276.1% | – | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -246% | – | – | – |
| EPS Diluted | -2.33 | -4.47 | -4.48 | -3.72 |
| % Growth | 47.9% | 0.2% | -20.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |